

Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?

Submission date 27/04/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 13/05/2009	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 26/04/2019	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Stephen Atkin

Contact details
HS Brocklehurst Building
Hull Royal Infirmary
Anlaby Road
Hull
United Kingdom
HU3 2RW

Additional identifiers

Protocol serial number
R0794

Study information

Scientific Title

Are early and late cardiovascular risk markers in women with polycystic ovary syndrome (PCOS) increased with concomitant non-alcoholic steatohepatitis (NASH) and can this be modified with exenatide?: An interventional open parallel single-centre trial

Acronym

PCOS NASH 2009

Study objectives

Early and late cardiovascular risk markers are exaggerated in women with both polycystic ovary syndrome (PCOS) and non-alcoholic steatohepatitis (NASH) compared to either condition alone, and these can be modified by therapy reflected in an improvement in endothelial dysfunction, fibrin clot structure and function and an improvement in inflammation histologically.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Leeds East Research Ethics Committee, 09/03/2009, ref: 09/H1306/9

Study design

Interventional open parallel single-centre trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Polycystic ovary syndrome, non-alcoholic steatohepatitis

Interventions

Twelve patients will be recruited for each of the three groups: 1) PCOS only, 2) NASH only and 3) PCOS with NASH (total n = 36).

Exenatide 5 mcg subcutaneously (sc) twice a day (bd) for 1 month then exenatide 10 mcg sc bd for 3 months.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Exenatide

Primary outcome(s)

1. To show that the combination of PCOS and NASH significantly amplifies cardiovascular risk markers compared to either PCOS or NASH alone
2. To show that intervention with exenatide significantly improves insulin resistance (an adverse cardiovascular risk marker)

All primary and secondary outcomes will be assessed in September 2010.

Key secondary outcome(s)

1. To show that intervention with exenatide significantly improves endothelial function (Early manifestation of cardiovascular disease) in subjects with PCOS and NASH
2. To determine if exenatide therapy significantly improves fibrin clot structure and function (Late manifestation of cardiovascular disease) in subjects with PCOS and NASH
3. To determine if exenatide is effective in reducing steatohepatitis by Fibroscan® and reduces the markers of liver fibrosis

All primary and secondary outcomes will be assessed in September 2010.

Completion date

30/09/2010

Eligibility

Key inclusion criteria

For PCOS:

1. Polycystic ovary syndrome (defined by the Rotterdam criteria as 2 out of 3 of:
 - 1.1. Oligo/anovulation
 - 1.2. Clinical or biochemical evidence of hirsutism, and/or
 - 1.3. Polycystic ovaries on ultrasound
2. Raised alanine aminotransferase (ALT)
3. Female, age 16-45 years

For NASH:

1. Patients with confirmed NASH
2. Female
3. Age 16-45 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Female

Total final enrolment

20

Key exclusion criteria

1. Ketoacidosis
2. Severe gastrointestinal disease
3. Type 2 diabetes
4. Hypothyroidism
5. Subjects taking regular prescribed medication
6. Not using a reliable method on contraception (eg barrier/oral contraceptive pill)
7. Patients not allowing disclosure to their GP's
8. History of pancreatitis
9. Chronic renal failure (creatinine clearance less than 60 ml/min or plasma creatinine >150 umol /L)
10. Pregnancy or breastfeeding women
11. Liver function tests >300% reference range normal (e.g., ALT >90 u/mL)
12. Acute conditions with the potential to alter renal function such as:
 - 12.1. Dehydration
 - 12.2. Severe infection
 - 12.3. Shock
 - 12.4. Intravascular administration of iodinated contrast

Date of first enrolment

01/05/2009

Date of final enrolment

30/09/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

HS Brocklehurst Building

Hull

United Kingdom

HU3 2RW

Sponsor information

Organisation

Hull and East Yorkshire Hospitals NHS Trust (UK)

ROR

<https://ror.org/01b11x021>

Funder(s)

Funder type

University/education

Funder Name

Diabetes Endowment Fund, University of Hull (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	02/04/2019	26/04/2019	Yes	No
HRA research summary			28/06/2023	No	No